foscarnet has been researched along with Stomatitis, Herpetic in 9 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Stomatitis, Herpetic: Stomatitis caused by Herpesvirus hominis. It usually occurs as acute herpetic stomatitis (or gingivostomatitis), an oral manifestation of primary herpes simplex seen primarily in children and adolescents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| " The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily." | 6.42 | Management of acyclovir-resistant herpes simplex virus. ( Chilukuri, S; Rosen, T, 2003) |
| " Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated." | 4.79 | Viral lesions of the mouth in HIV-infected patients. ( Itin, PH; Lautenschlager, S, 1997) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| " The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily." | 2.42 | Management of acyclovir-resistant herpes simplex virus. ( Chilukuri, S; Rosen, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, T | 2 |
| Chilukuri, S | 1 |
| Baumann, R | 1 |
| Wunderli, W | 1 |
| Riess, C | 1 |
| Vogt, M | 1 |
| Iino, T | 1 |
| Gondo, H | 1 |
| Ohno, Y | 1 |
| Minagawa, H | 1 |
| Iwasaki, H | 1 |
| Maruyama, T | 1 |
| Nakashima, H | 1 |
| Niho, Y | 1 |
| Itin, PH | 1 |
| Lautenschlager, S | 1 |
| Darville, JM | 1 |
| Ley, BE | 1 |
| Roome, AP | 1 |
| Foot, AB | 1 |
| Safrin, S | 1 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Davis, R | 1 |
| Hafner, R | 1 |
| Rush, J | 1 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| Mills, J | 2 |
| MacPhail, LA | 1 |
| Greenspan, D | 1 |
| Schiødt, M | 1 |
| Drennan, DP | 1 |
| Vinckier, F | 1 |
| Boogaerts, M | 1 |
| De Clerck, D | 1 |
| De Clercq, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for foscarnet and Stomatitis, Herpetic
| Article | Year |
|---|---|
Management of acyclovir-resistant herpes simplex virus.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Viral; Foscarnet; Herpes Simplex; | 2003 |
Viral lesions of the mouth in HIV-infected patients.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cytomegalovirus In | 1997 |
1 trial available for foscarnet and Stomatitis, Herpetic
| Article | Year |
|---|---|
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
6 other studies available for foscarnet and Stomatitis, Herpetic
| Article | Year |
|---|---|
Recurrent Herpes Labialis in Adults: New Tricks for an Old Dog.
Topics: Acyclovir; Administration, Oral; Administration, Topical; Adult; Antiviral Agents; Chronic Disease; | 2017 |
[Acyclovir-resistant Herpes simplex viruses in HIV-infected patients].
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Female; Foscarn | 1993 |
Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation.
Topics: Acyclovir; Adult; Antiviral Agents; Bone Marrow Transplantation; Drug Resistance, Microbial; Foscarn | 1996 |
Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Child; Drug Resistance, | 1998 |
Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Candidiasis, Oral; Drug Resi | 1989 |
Chronic herpetic infection in an immunocompromised patient: report of a case.
Topics: Acyclovir; Antiviral Agents; Bromodeoxyuridine; Chronic Disease; Foscarnet; Humans; Immunosuppressio | 1987 |